title: Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1.
abstract: We have recently shown that induction of the p53 tumour suppressor protein by the small-molecule RITA (reactivation of p53 and induction of tumour cell apoptosis; 2,5-bis(5-hydroxymethyl-2-thienyl)furan) inhibits hypoxia-inducible factor-1α and vascular endothelial growth factor expression in vivo and induces p53-dependent tumour cell apoptosis in normoxia and hypoxia. Here, we demonstrate that RITA activates the canonical ataxia telangiectasia mutated/ataxia telangiectasia and Rad3-related DNA damage response pathway. Interestingly, phosphorylation of checkpoint kinase (CHK)-1 induced in response to RITA was influenced by p53 status. We found that induction of p53, phosphorylated CHK-1 and γH2AX proteins was significantly increased in S-phase. Furthermore, we found that RITA stalled replication fork elongation, prolonged S-phase progression and induced DNA damage in p53 positive cells. Although CHK-1 knockdown did not significantly affect p53-dependent DNA damage or apoptosis induced by RITA, it did block the ability for DNA integrity to be maintained during the immediate response to RITA. These data reveal the existence of a novel p53-dependent S-phase DNA maintenance checkpoint involving CHK-1.
authors: Department of Metabolism and Experimental Therapeutics, Division of Medicine, Centre for Cell Signalling and Molecular Genetics, University College London, Rayne Building, 5 University Street, London WC1E 6JJ, UK.
authors: A
authors: A
authors: Ahmed
authors: J
authors: J
authors: Yang
authors: A
authors: A
authors: Maya-Mendoza
authors: D A
authors: DA
authors: Jackson
authors: M
authors: M
authors: Ashcroft
references: Genes Dev. 2000 Jan 1;14(1):34-44
references: 10640274
references: Cancer Res. 2000 Oct 15;60(20):5630-4
references: 11059752
references: Mol Cell. 2003 Apr;11(4):997-1008
references: 12718885
references: Curr Cancer Drug Targets. 2006 May;6(3):197-205
references: 16712457
references: Biochem Pharmacol. 1999 Jun 1;57(11):1283-95
references: 10230772
references: Mol Cell Biol. 2009 Apr;29(8):2243-53
references: 19223463
references: Curr Biol. 2003 Jun 17;13(12):R468
references: 12814562
references: Nat Cell Biol. 2005 Feb;7(2):195-201
references: 15665856
references: Cancer Cell. 2009 Mar 3;15(3):171-83
references: 19249676
references: Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93
references: 16443686
references: Oncogene. 2006 Aug 31;25(39):5359-69
references: 16619043
references: Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13777-82
references: 10570149
references: DNA Repair (Amst). 2007 Jul 1;6(7):953-66
references: 17531546
references: Oncogene. 2006 Sep 28;25(44):5921-32
references: 16682953
references: Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14775-80
references: 9843965
references: Mol Cell Biol. 1999 Mar;19(3):1751-8
references: 10022862
references: Science. 2004 Feb 6;303(5659):844-8
references: 14704432
references: Nat Med. 2004 Dec;10(12):1321-8
references: 15558054
references: J Biol Chem. 2004 May 7;279(19):20067-75
references: 14982920
references: Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9891-6
references: 16788066
references: Science. 1998 Nov 20;282(5393):1497-501
references: 9822382
references: Nat Cell Biol. 2007 Apr;9(4):391-401
references: 17384638
references: Mol Cell Biol. 2004 Jul;24(13):5757-66
references: 15199132
references: Mol Cell. 2010 Oct 22;40(2):294-309
references: 20965423
references: Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16090-5
references: 20805465
references: Mol Cell Biol. 2006 Apr;26(8):3319-26
references: 16581803
references: EMBO J. 2010 Oct 20;29(20):3558-70
references: 20834228
references: Cancer Res. 2006 Jun 15;66(12):6264-70
references: 16778202
references: Cell Cycle. 2009 May 15;8(10):1630-2
references: 19372763
references: Nature. 1996 Jan 4;379(6560):88-91
references: 8538748
references: Expert Rev Mol Med. 2009 Aug 27;11:e26
references: 19709449
references: J Biol Chem. 1999 Mar 19;274(12):8039-45
references: 10075703
references: EMBO J. 2003 Mar 3;22(5):1210-22
references: 12606585
references: Ann Med. 2003;35(7):458-65
references: 14649328
references: J Cell Biol. 1998 Mar 23;140(6):1285-95
references: 9508763
references: EMBO J. 2007 Jun 6;26(11):2719-31
references: 17491592
references: Mol Pharmacol. 1999 Sep;56(3):478-84
references: 10462535
references: Science. 1999 Dec 24;286(5449):2507-10
references: 10617466
references: Oncogene. 2010 Feb 4;29(5):625-34
references: 19946328